Postmarketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease
NCT02238158 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 595
Last updated 2014-09-12
Summary
To obtain further information on the tolerability and efficacy of Atrovent® inhalets in long term treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
- DRUG
-
Atrovent® inhalets
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 40 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1999-09-30
- Primary Completion
- 2001-04-30
More Related Trials
-
Postmarketing Surveillance Study of Atrovent® in Chronic Obstructive Airways Disease
NCT02236715 ·Status: COMPLETED
-
Postmarketing Surveillance Study of Anticholinergics - Prescribing Pattern and Therapeutic Long Term Value in Patients Suffering From Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT02238184 ·Status: COMPLETED
-
Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease
NCT02232594 ·Status: COMPLETED
-
Post-marketing Surveillance of Ventilat® in Long-term Therapy in Chronic Obstructive Pulmonary Disease
NCT02233907 ·Status: COMPLETED
-
Post-marketing Surveillance of Ventilat® Metered Dose Inhaler in Chronic Obstructive Bronchitis
NCT02233920 ·Status: COMPLETED
-
Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Airways Disease
NCT02231424 ·Status: COMPLETED
-
Postmarketing Surveillance Study of Berotec® N 100 µg Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease
NCT02244216 ·Status: COMPLETED
-
Post-marketing Surveillance of Berodual® Metered-dose Inhaler in the Treatment of Chronic Obstructive Respiratory Tract Disease
NCT02231437 ·Status: COMPLETED
-
PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT01350128 ·Status: COMPLETED ·Phase: PHASE2
-
Trial to Determine the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to ATROVENT® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT02236169 ·Status: COMPLETED ·Phase: PHASE2
-
Actuation Indicator Trial in Patients With COPD
NCT00928746 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT01415518 ·Status: COMPLETED ·Phase: PHASE4
-
Study of the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to the Market Standard, Atrovent® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease
NCT02260011 ·Status: COMPLETED ·Phase: PHASE2
-
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
NCT02552160 ·Status: COMPLETED
-
Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993 in Healthy Volunteers
NCT02743013 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers
NCT02359292 ·Status: COMPLETED ·Phase: PHASE1
-
Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.
NCT04078126 ·Status: COMPLETED ·Phase: PHASE3
-
Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult Patients
NCT01803087 ·Status: COMPLETED ·Phase: PHASE2
-
A Drug Utilisation Post-authorisation Study of New Users of Aclidinium Bromide (Monotherapy or in Combination)
NCT03333018 ·Status: COMPLETED
-
Study in Patients With COPD
NCT00215384 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Tiotropium and Atrovent in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT02172469 ·Status: COMPLETED ·Phase: PHASE3
-
Combined Bronchodilators in Chronic Obstructive Pulmonary Disease and the Risk of Adverse Cardio-pulmonary Events
NCT02096731 ·Status: COMPLETED
-
Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects
NCT02573155 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic Interaction Study of Glycopyrrolate and Formoterol in Healthy Volunteers
NCT01398111 ·Status: COMPLETED ·Phase: PHASE1
-
Influence Of Different Airflow Resistances On Drug Effect Of 50μg Salmeterol And 6 μg Formoterol
NCT00327353 ·Status: COMPLETED ·Phase: PHASE4